The p-Tau217 assay runs on the DxI 9000 Immunoassay Analyzer, enabling laboratories to incorporate blood-based Alzheimer’s biomarker testing into high-throughput workflows.
The non-invasive test could reduce the need for surgical biopsies by more than 90% for patients with suspicious mouth lesions.
The test detect signs of colorectal cancer and precancerous growths using a home collection kit.
A prospective study shows the test more accurately identifies patients who may safely avoid biopsy compared to the Melanoma Institute Australia nomogram.
The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.
The patent covers a gene-expression profiling method designed to identify patients most likely to respond to the investigational therapy stenoparib through 2042.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures enzyme activity in plasma to help clinicians identify acute ischemic stroke, which is often missed by standard imaging.
The study highlights the role of brain-derived nanoparticles in identifying the disease through minimally invasive testing.
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.